GetTopicDetailResponse(id=7a3e11181ea4, topicName=西米普利單抗, introduction=西米普利單抗, content=皮膚鱗狀細胞癌 2期臨床試驗 西米普利單抗, image=null, comments=0, allHits=1005, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Sat Mar 02 09:40:57 CST 2024, time=2024-03-02, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=111877, tagList=[TagDto(tagId=111877, tagName=西米普利單抗)], ipAttribution=上海, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2260549, encodeId=ddb7226054973, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小細胞肺癌#</a> <a href='/topic/show?id=7a3e11181ea4' target=_blank style='color:#2F92EE;'>#西米普利單抗#</a>, objectTitle=5年存活患者幾乎翻倍，死亡風(fēng)險降低41%！新藥為晚期肺癌患者帶來持久顯著獲益, objectType=article, longId=871934, objectId=1bb38e19341d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240517/1715930918928_5579292.jpg, objectUrl=/article/show_article.do?id=1bb38e19341d, replyNumber=0, likeNumber=36, createdTime=2025-04-15, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bb38e19341d, moduleTitle=5年存活患者幾乎翻倍，死亡風(fēng)險降低41%！新藥為晚期肺癌患者帶來持久顯著獲益, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=1bb38e19341d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2257392, encodeId=4d8a225e39257, content=<a href='/topic/show?id=7a3e11181ea4' target=_blank style='color:#2F92EE;'>#西米普利單抗#</a> <a href='/topic/show?id=58c5125368c3' target=_blank style='color:#2F92EE;'>#復(fù)發(fā)/難治性結(jié)外NK/T細胞淋巴瘤（r/r ENKTL）#</a> <a href='/topic/show?id=9bee1141e2fc' target=_blank style='color:#2F92EE;'>#艾沙妥昔單抗#</a>, objectTitle=Blood：II期臨床試驗揭示西米普利單抗和艾沙妥昔單抗聯(lián)合治療在復(fù)發(fā)/難治性NK/T細胞淋巴瘤中的療效, objectType=article, longId=868635, objectId=f9c5868635e9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250323/1742709396523_6145188.jpg, objectUrl=/article/show_article.do?id=f9c5868635e9, replyNumber=0, likeNumber=38, createdTime=2025-03-23, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=f9c5868635e9, moduleTitle=Blood：II期臨床試驗揭示西米普利單抗和艾沙妥昔單抗聯(lián)合治療在復(fù)發(fā)/難治性NK/T細胞淋巴瘤中的療效, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f9c5868635e9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2257403, encodeId=a553225e4036c, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小細胞肺癌#</a> <a href='/topic/show?id=7a3e11181ea4' target=_blank style='color:#2F92EE;'>#西米普利單抗#</a> <a href='/topic/show?id=7be811240250' target=_blank style='color:#2F92EE;'>#5年隨訪結(jié)果#</a>, objectTitle=西米普利單抗單藥治療作為PD-L1表達≥50%的晚期非小細胞肺癌患者一線治療的五年隨訪結(jié)果：EMPOWER-Lung 1研究, objectType=article, longId=868327, objectId=3c9486832e99, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250121/1737454189523_8538692.png, objectUrl=/article/show_article.do?id=3c9486832e99, replyNumber=0, likeNumber=41, createdTime=2025-03-23, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=3c9486832e99, moduleTitle=西米普利單抗單藥治療作為PD-L1表達≥50%的晚期非小細胞肺癌患者一線治療的五年隨訪結(jié)果：EMPOWER-Lung 1研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=3c9486832e99)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2190542, encodeId=668a219054275, content=<a href='/topic/show?id=e101e2133b1' target=_blank style='color:#2F92EE;'>#皮膚鱗狀細胞癌#</a> <a href='/topic/show?id=5110111998' target=_blank style='color:#2F92EE;'>#2期臨床試驗#</a> <a href='/topic/show?id=7a3e11181ea4' target=_blank style='color:#2F92EE;'>#西米普利單抗#</a>, objectTitle=Lancet Oncol | 2期臨床研究：新輔助西米普利單抗在可切除II-IV期皮膚鱗狀細胞癌患者中的安全性和療效評估, objectType=article, longId=815535, objectId=72448155354d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240301/1709304284017_6145188.jpg, objectUrl=/article/show_article.do?id=72448155354d, replyNumber=0, likeNumber=141, createdTime=2024-03-02, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=72448155354d, moduleTitle=Lancet Oncol | 2期臨床研究：新輔助西米普利單抗在可切除II-IV期皮膚鱗狀細胞癌患者中的安全性和療效評估, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=72448155354d)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2024-03-02發(fā)表于上海
